2020-09-14 / News
3SBio Announces Acceptance of IND application for bevacizumab biosimilar in China
Marketing authorization for SB8 was granted by the European Commission on Aug 19, 2020.
2020-09-01 / News
3SBio MSCI ESG Rating Upgraded to A, Ranking at the Forefront of the Global Biotechnology Industry
The upgradation of 3Sbio's ESG rating is not only the recognition of 3Sbio 's ESG management level, ...
2020-08-17 / News
3SBio Maintains Steady Growth in 1H 2020 More than 10 NDAs to be submitted in the next 3 years
We aim to become a world-leading Chinese biopharmaceutical company, and continuously improve the ava...
2020-06-28 / News
Sunshine Guojian obtained clinical trial approval by the FDA for the anti-IL-4Rα monoclonal antibody
2020-06-19 / News
Breaking the monopoly of imported anti-HER2 monoclonal antibody drugs Approval obtained for “Inetetamab”, the first innovative anti-HER2 monoclonal antibody independently developed in China
2020-03-31 / News
3SBio Unveils 2019 Annual Results：Revenue Rises by 16.0%, Normalized Net Profit Jumps by19.4%, R&D Expenses Soar 45.2%